These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 25568561)

  • 1. Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia.
    Buturovic BA; Ristic LB; Narancic AM
    Med Arch; 2014 Oct; 68(5):313-6. PubMed ID: 25568561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes.
    Gastaldelli A; Nauck MA; Balena R
    Metabolism; 2013 Sep; 62(9):1330-9. PubMed ID: 23831441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
    Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
    Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease.
    Liu Y; Jiang X; Chen X
    Lipids Health Dis; 2017 Dec; 16(1):227. PubMed ID: 29197387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).
    Mathieu C; Rodbard HW; Cariou B; Handelsman Y; Philis-Tsimikas A; Ocampo Francisco AM; Rana A; Zinman B;
    Diabetes Obes Metab; 2014 Jul; 16(7):636-44. PubMed ID: 24443830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The PROROK project results after 6 months of intervention (Prospective observation project focusing on the relevance of the difference between fasting blood glucose levels and postprandial blood glucose for estimation of success of type 2 diabetes therapy)].
    -Žďarská DJ; Piťhová P; Pavlík T; Kvapil M
    Vnitr Lek; 2015 Nov; 61(11 Suppl 3):3S44-9. PubMed ID: 26652965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges.
    King AB; Philis-Tsimikas A; Kilpatrick ES; Langbakke IH; Begtrup K; Vilsbøll T
    Diabetes Technol Ther; 2017 Apr; 19(4):255-264. PubMed ID: 28282219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effect of liraglutide and metformin therapy on the disease regulation and weight loss in obese patients with Type 2 diabetes mellitus.
    Keskin L; Yaprak B
    Eur Rev Med Pharmacol Sci; 2022 Sep; 26(18):6813-6820. PubMed ID: 36196729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of basal insulin analog and metformin on glycaemia control and weight as risk factors for endothelial dysfunction.
    Ascić-Buturović B; Kacila M
    Bosn J Basic Med Sci; 2008 Nov; 8(4):309-12. PubMed ID: 19125700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The effect of metformin on fasting and postprandial insulin secretion in obese patients with diabetes mellitus type 2].
    Vuković M; Lapcević M; Kalezić N; Gvozdenović BS
    Srp Arh Celok Lek; 2007; 135(7-8):447-52. PubMed ID: 17929538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of therapeutic effect of metformin hydrochloride/vildagliptin and liraglutide on type 2 diabetes mellitus in obese patients].
    Zhou B; Li J; Fang C; Huang Y; Sang G; Tao S; He C
    Nan Fang Yi Ke Da Xue Xue Bao; 2023 Mar; 43(3):436-442. PubMed ID: 37087589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study.
    Díaz-Soto G; de Luis DA; Conde-Vicente R; Izaola-Jauregui O; Ramos C; Romero E
    Diabetes Res Clin Pract; 2014 Apr; 104(1):92-6. PubMed ID: 24530118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
    Forst T; Anastassiadis E; Diessel S; Löffler A; Pfützner A
    Diabetes Metab Res Rev; 2014 Oct; 30(7):582-9. PubMed ID: 24459063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin.
    Chamarthi B; Cincotta AH
    Postgrad Med; 2017 May; 129(4):446-455. PubMed ID: 28374645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined metformin and insulin therapy for patients with type 2 diabetes mellitus.
    Ponssen HH; Elte JW; Lehert P; Schouten JP; Bets D
    Clin Ther; 2000 Jun; 22(6):709-18. PubMed ID: 10929918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes.
    Anholm C; Kumarathurai P; Pedersen LR; Nielsen OW; Kristiansen OP; Fenger M; Madsbad S; Sajadieh A; Haugaard SB
    Diabetes Obes Metab; 2017 Jun; 19(6):850-857. PubMed ID: 28124822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test.
    Holst JJ; Buse JB; Rodbard HW; Linjawi S; Woo VC; Boesgaard TW; Kvist K; Gough SC
    J Diabetes Sci Technol; 2015 Oct; 10(2):389-97. PubMed ID: 26443290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.
    Nauck MA; Hompesch M; Filipczak R; Le TD; Zdravkovic M; Gumprecht J;
    Exp Clin Endocrinol Diabetes; 2006 Sep; 114(8):417-23. PubMed ID: 17039422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.